Jazz Pharmaceuticals plc (Ireland) (JAZZ) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

JAZZ scores 47 out of 100, a D grade, labeled "Roarable Sell — Underperform / Distribution Warning." The five pillars are:

• Fundamental Cash Engine: 10 / 20. this pillar reflects ROIC of -4.7% and an FCF yield of 9.61%. The cash generation signal is positive, but returns on invested capital are negative, so the cash yield is not translating into value creation on the capital base.
• Whale 13F Flow: 8 / 20. this pillar covers institutional accumulation and options positioning. The score is weak, indicating limited institutional conviction in the source data.
• Insider Conviction: 13 / 20. this pillar covers SEC Form 4 and Congressional PTR cluster flow. It is the strongest pillar, though still below the midpoint.
• Macro Regime Fit: 7 / 20. beta is 1.09 and sector sensitivity is noted. The weak score suggests the stock carries amplified exposure to broader market swings without a clear macro tailwind.
• Forensic Balance Sheet: 9 / 20. the Altman Z-Score is 1.97, the Piotroski F-Score is 7/9, and Debt/Equity is 1. The Piotroski reading is solid, but the Altman reading sits in a range that warrants caution.

For a prospective investor evaluating the stock today, the rating points to a cash-generative business whose accounting profitability, return on capital, and institutional support are all weak. Upside drivers would need to come from a reversal in operating earnings and institutional demand. Valuation tradeoffs are visible: the forward P/E of 36 is elevated relative to negative trailing EPS, so the price already embeds expectations that the reported figures do not yet show.

Trades under JAZZ on NASDAQ. It sits in the Health Care sector and the Biotechnology: Pharmaceutical Preparations industry. —

Revenue rose from $3.83B in FY 2023 to $4.27B in FY 2025, while operating income swung from positive in FY 2024 to -$430.2M in FY 2025. Per the market data, operating margin is -10.1% and net margin is -8.3%, with gross margin reported as 0%. The Altman Z-Score is 1.97 and the Piotroski F-Score is 7/9. Debt fell from $6.08B in FY 2024 to $4.33B in FY 2025, and cash fell from $2.41B to $1.39B over the same period.

• 🐂 Primary Bull Case: Free cash flow of $1.30B in FY 2025 and a 9.61% FCF yield show the business still generates meaningful cash despite accounting losses. With Fundamental Cash Engine at 10/20 (ROIC -4.7%, FCF yield 9.61%) and Institutional Whale Flow at 10/20, sustained execution supports upside toward the top of the $128.80 – $266.38 52-week range.
• 🐻 Primary Bear Case: Operating income swung to -$430.2M in FY 2025 with ROIC at -4.7%, while the RQD rating places the stock in a Sell category with weak institutional flow. Investors must weigh current valuation against -10.1% operating margins and a 1.09 macro beta if sector demand softens.

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), JAZZ carries a macro regime beta of 1.09 and gross margin of —.

• Key Question #1: What drove the swing from positive FY 2024 operating income of $716.6M to negative FY 2025 operating income of -$430.2M?
• Key Question #2: Why is EPS reported as N/A for every period despite the net income figures provided?
• Key Question #3: What explains the drop in cash from $2.41B to $1.39B alongside the reduction in debt?